Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,015,106 papers from all fields of science
Search
Sign In
Create Free Account
TMC 435
Known as:
435, TMC
, TMC-435
, TMC435
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
simeprevir
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Simeprevir (TMC435) once daily with peginterferon‐α‐2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO‐4 study
H. Kumada
,
N. Hayashi
,
+8 authors
Shoichiro Goto
Hepatology Research
2015
Corpus ID: 8882591
The efficacy and safety of simeprevir in combination with peginterferon‐α‐2b and ribavirin (PEG IFN‐α‐2b/RBV) were investigated…
Expand
2015
2015
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants
T. Verbinnen
,
B. Fevery
,
L. Vijgen
,
T. Jacobs
,
S. De Meyer
,
O. Lenz
Antimicrobial Agents and Chemotherapy
2015
Corpus ID: 23057553
ABSTRACT Simeprevir (TMC435) is a once-daily, single-pill, oral hepatitis C virus (HCV) NS3 protease inhibitor approved for the…
Expand
2013
2013
Sa2073 SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders
E. Lawitz
,
R. Ghalib
,
+7 authors
K. Lindsay
2013
Corpus ID: 74694515
2013
2013
887 PHARMACOKINETICS OF SIMEPREVIR (TMC435) IN VOLUNTEERS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT
S. Ouwerkerk-Mahadevan
,
A. Simion
,
K. Spittaels
,
M. Mauviel
2013
Corpus ID: 71916989
Review
2012
Review
2012
TMC435 for the treatment of chronic hepatitis C
S. Tanwar
,
P. Trembling
,
G. Dusheiko
Expert Opinion on Investigational Drugs
2012
Corpus ID: 31293275
Introduction: Chronic hepatitis C (CHC) virus infection affects more than 170 million people globally. The aim of treatment of…
Expand
2011
2011
1221 TREATMENT OUTCOME AND RESISTANCE ANALYSIS IN HCV GENOTYPE 1 PATIENTS PREVIOUSLY EXPOSED TO TMC435 MONOTHERAPY AND RE-TREATED WITH TMC435 IN COMBINATION WITH PEGIFNα-2A/RIBAVIRIN
O. Lenz
,
J. Bruijne
,
+10 authors
H. Reesink
2011
Corpus ID: 71230699
Review
2011
Review
2011
Emerging therapeutic options in hepatitis C virus infection.
F. Poordad
,
V. Khungar
American Journal of Managed Care
2011
Corpus ID: 22187884
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is pegylated interferon alfa in…
Expand
2010
2010
Haemo- and cytocompatibility of bioresorbable homo- and copolymers prepared from 1,3-trimethylene carbonate, lactides, and epsilon-caprolactone.
Jian Yang
,
Feng Liu
,
+5 authors
Suming Li
Journal of Biomedical Materials Research. Part A
2010
Corpus ID: 205985120
A series of bioresorbable polymers were prepared by ring-opening polymerization of L-lactide (LLA), DL-lactide (DLLA), epsilon…
Expand
2010
2010
1075 PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) ANALYSES OF TMC435 IN TREATMENT-NAIVE HEPATITIS C (HCV)-INFECTED PATIENTS IN THE OPERA-1 STUDY
V. Sekar
,
P. Vis
,
O. Lenz
,
P. Meyvisch
,
M. Peeters
,
G. Smedt
2010
Corpus ID: 73152579
Review
2009
Review
2009
TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
Y. Tsantrizos
Current opinion in investigational drugs
2009
Corpus ID: 45342351
TMC-435, being developed by Tibotec Pharmaceuticals Ltd, is an orally administered, macrocyclic inhibitor of the HCV NS3/4A…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE